Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.

Manzari MT, Anderson GR, Lin KH, Soderquist RS, Çakir M, Zhang M, Moore CE, Skelton RN, Fèvre M, Li X, Bellucci JJ, Wardell SE, Costa SA, Wood KC, Chilkoti A.

Sci Adv. 2019 Sep 4;5(9):eaaw9162. doi: 10.1126/sciadv.aaw9162. eCollection 2019 Sep.

2.

Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines.

Hajighasemlou S, Alebouyeh M, Rastegar H, Manzari MT, Mirmoghtadaei M, Moayedi B, Ahmadzadeh M, Parvizpour F, Johari B, Naeini MM, Farajollahi MM.

Asian Pac J Cancer Prev. 2015;16(14):5977-81.

3.

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD.

J Mol Biol. 2012 Sep 28;422(4):532-44. doi: 10.1016/j.jmb.2012.06.014. Epub 2012 Jun 15.

Supplemental Content

Loading ...
Support Center